These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32223524)

  • 1. Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.
    Latimer NR; White IR; Tilling K; Siebert U
    Stat Methods Med Res; 2020 Oct; 29(10):2900-2918. PubMed ID: 32223524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
    Latimer NR; Abrams KR; Siebert U
    BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
    Latimer NR; White IR; Abrams KR; Siebert U
    Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.
    Latimer NR; Dewdney A; Campioni M
    BMC Med Res Methodol; 2024 Jan; 24(1):17. PubMed ID: 38253996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.
    Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
    Stat Methods Med Res; 2017 Apr; 26(2):724-751. PubMed ID: 25416688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.
    Latimer NR; Abrams KR; Lambert PC; Morden JP; Crowther MJ
    Stat Methods Med Res; 2018 Mar; 27(3):765-784. PubMed ID: 27114326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.
    Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
    Med Decis Making; 2014 Apr; 34(3):387-402. PubMed ID: 24449433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
    Fukuda M; Sakamaki K; Oba K
    Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bias and Type I error Control in Correcting Treatment Effect for Treatment Switching Using Marginal Structural Models in Phase III Oncology Trials.
    Xu J; Liu G; Wang B
    J Biopharm Stat; 2022 Nov; 32(6):897-914. PubMed ID: 35656809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
    Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting.
    Sullivan TR; Latimer NR; Gray J; Sorich MJ; Salter AB; Karnon J
    Value Health; 2020 Mar; 23(3):388-396. PubMed ID: 32197735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Evans R; Hawkins N; Dequen-O'Byrne P; McCrea C; Muston D; Gresty C; Ghate SR; Fan L; Hettle R; Abrams KR; de Bono J; Hussain M; Agarwal N
    Target Oncol; 2021 Sep; 16(5):613-623. PubMed ID: 34478046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.
    Latimer NR; Abrams KR; Amonkar MM; Stapelkamp C; Swann RS
    Oncologist; 2015 Jul; 20(7):798-805. PubMed ID: 26040620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Validation Study of the Rank-Preserving Structural Failure Time Model: Confidence Intervals and Unique, Multiple, and Erroneous Solutions.
    Ouwens M; Hauch O; Franzén S
    Med Decis Making; 2018 May; 38(4):509-519. PubMed ID: 29607730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rpsftm: An R Package for Rank Preserving Structural Failure Time Models.
    Allison A; White IR; Bond S
    R J; 2017 Dec; 9(2):342-353. PubMed ID: 29564164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjusting overall survival for treatment switches: commonly used methods and practical application.
    Watkins C; Huang X; Latimer N; Tang Y; Wright EJ
    Pharm Stat; 2013; 12(6):348-57. PubMed ID: 24136868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.
    Di Scala L; Bacchi M; Bayer B; Turricchia S
    Adv Ther; 2022 Sep; 39(9):4346-4358. PubMed ID: 35917059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Power and sample sizes estimation in clinical trials with treatment switching in intention-to-treat analysis: a simulation study.
    Deng L; Hsu CY; Shyr Y
    BMC Med Res Methodol; 2023 Feb; 23(1):49. PubMed ID: 36823545
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.